Efficacy and Safety of Anti–Interleukin‐20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 6, 2015-06 ,pp. : 1438-1448

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis

By Gottlieb Alice B.   Cooper Kevin D.   McCormick Thomas S.   Toichi Eiko   Everitt Daniel E.   Frederick Bart   Zhu Yaowei   Pendley Charles E.   Graham Martin A.   Mascelli Mary Ann  

Current Medical Research and Opinion, Vol. 23, Iss. 5, 2007-05 ,pp. : 1081-1092

Informa Healthcare

Access to resources Recommend Favorite

Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 177, Iss. 6, 2017-12 ,pp. : 1537-1551

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalating Phase I, Healthy Subjects Study of Intravenous OPN‐305, a Humanized Anti‐TLR2 Antibody

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 5, 2013-11 ,pp. : 593-600

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of disease‐mediated therapeutic protein–drug interactions between an anti–interleukin‐6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 12, 2015-12 ,pp. : 1386-1394

John Wiley & Sons Inc

Access to resources Recommend Favorite